Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Budget Limits Mean Personnel Cuts Likely; 15% Reduction in Admin

Executive Summary

The Center for Drug Evaluation & Research will likely cut administrative and information technology personnel to meet fiscal year 2004 budget constraints, Director Janet Woodcock, MD, says

You may also be interested in...

AHRQ Comparative Trial Funding Awaits Supplemental Appropriation

The comparative trial/cost effectiveness provisions in the Medicare legislation will require a supplemental appropriation for the Agency for Healthcare Research & Quality

FDA Drug Safety Upgrades Coming; Medicare Bill Could Help Win Funding

The Medicare prescription drug coverage legislation should help FDA make the case for additional funding for post-marketing surveillance, according to Center for Drug Evaluation & Research Acting Director Steven Galson, MD

CDER Deputy Galson Will Run Drug Center For At Least Six Months

Center for Drug Evaluation & Research Deputy Director Steve Galson, MD, will be acting center director during the period when FDA is expected to announce a decision on forced Rx-to-OTC switches




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts